New drugs for Alzheimer’s disease

A new drug for Alzheimer’s disease developed by Ocean University of China, Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences and Shanghai Green Valley Pharmaceutical Co., Ltd. has been approved by the State Drug Administration, which can be used for mild to moderate Alzheimer’s disease and improve cognitive function of patients, the reporter learned from Shanghai Institute of medicine of Chinese Academy of Sciences on Tuesday. The drug is the first time in the world and will provide new treatment options for patients.
Geng Meiyu, a researcher from Shanghai Institute of medicine, Chinese Academy of Sciences, led the team to develop the original new drug named “nine phase one” (mannose sodium, code name gv-971) for 22 years, which was successfully developed under the continuous efforts of China Ocean University, Shanghai Institute of medicine, Chinese Academy of Sciences and Shanghai Green Valley pharmaceutical.
Alzheimer’s disease is commonly known as Alzheimer’s disease, once the disease, people’s memory, thinking and judgment ability will be like the “eraser” in the mind slowly wiped away. According to the international Alzheimer’s Association, there are about 48 million patients in the world, and one new case will be added every three seconds. With the aging of the population, the harm of Alzheimer’s disease is more and more obvious.
Geng Meiyu (third from left), the main inventor of the new drug and researcher of Shanghai Institute of medicine, Chinese Academy of Sciences, and the research and development team are discussing their work (photo taken on January 2, 2019) Xinhua social development (picture provided by Shanghai Institute of medicine, Chinese Academy of Sciences)
There are only a few drugs for clinical treatment of Alzheimer’s disease in the world. Over the past 20 years, major pharmaceutical companies have invested heavily in the research and development of new drugs, most of which have failed. No new drugs have been launched in this field for 17 years.
It is understood that 1199 subjects participated in the phase 1, phase 2 and phase 3 clinical trials. Among them, the third phase of clinical practice was organized by the mental health center affiliated to the Medical College of Shanghai Jiaotong University and Beijing Union Medical College, and carried out in 34 third-class first-class hospitals across the country, with 818 subjects’ medication observation completed. The whole clinical trial is managed by AI kunwei, a global famous outsourcing service organization for new drug research and development.
A new drug for Alzheimer’s disease, “nine phase one” (ganlute sodium) (photo taken on November 2, 2019) Xinhua social development (picture provided by Shanghai Institute of medicine, Chinese Academy of Sciences)
The results of a 36 week three-phase clinical study showed that “nine phases one” can significantly improve cognitive impairment in patients with mild and moderate Alzheimer’s disease. Compared with the placebo group, the main efficacy index cognitive function improved significantly, cognitive function scale score improved by 2.54 points (P < 0.0001). The incidence of adverse events was similar to that of placebo group.
According to Geng Meiyu, the preclinical mechanism of action shows that “nine phases one” can improve cognitive dysfunction by reshaping the balance of intestinal flora, inhibiting the abnormal increase of specific metabolites of intestinal flora, reducing peripheral and central inflammation, reducing β – amyloid protein deposition and tau protein hyperphosphorylation. The unique mechanism of targeting brain gut axis provides an important scientific basis for deep understanding of the clinical effect of “nine phases one”.